ARTICLE | Financial News
Neurogene raises $68.5M series A for neurological disease gene therapies
February 12, 2019 12:05 PM UTC
Neurogene Inc. (New York, N.Y.) raised $68.5 million in a series A round to fund development of its adeno-associated viral (AAV)-based gene therapies to treat rare neurological diseases.
Samsara BioCapital, EcoR1 Capital, Cormorant Asset Management, Redmile Group and an undisclosed healthcare investment fund participated in the round...
BCIQ Company Profiles